Pipeline
| Regimen | Indication | Study Name | Phase 1 | Phase 2 | Phase 3 | Commercial |
|---|---|---|---|---|---|---|
XPOVIO | ||||||
w/dexamethasone | Multiple myeloma (penta-refractory) | STORM |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
w/bortezomib + dexamethasone | Multiple myeloma (2L+) | BOSTON |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
monotherapy | DLBCL (R/R) | SADAL |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
SELINEXOR
| Regimen | Indication | Study Name | Phase 1 | Phase 2 | Phase 3 | Commercial |
|---|---|---|---|---|---|---|
SELINEXOR | ||||||
w/ruxolitinib | Myelofibrosis (JAKi-naïve) | SENTRY (XPORT-MF-034) |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
monotherapy | Endometrial cancer (maintenance; p53 wild-type) | XPORT-EC (XPORT-EC-042) |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
w/pomalidomide + dexamethasone | Multiple myeloma (2L+; post anti – CD38) | EMN29 (XPORT-MM-031) |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
monotherapy | Endometrial cancer (maintenance) | SIENDO (KCP-330-024) |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
w/R-GDP | DLBCL (R/R) | XPORT-DLBCL-030 |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
monotherapy | Myelofibrosis (JAKi-naïve) | SENTRY-2 (XPORT-MF-044) |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
w/standard approved agents | Multiple myeloma (relapsed/refractory) | STOMP (KCP-330-017) |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
ELTANEXOR
| Regimen | Indication | Study Name | Phase 1 | Phase 2 | Phase 3 | Commercial |
|---|---|---|---|---|---|---|
ELTANEXOR | ||||||
monotherapy | Myelodysplastic neoplasms (relapsed/refractory) | KCP-8602-801 |
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|
- Hematologic Cancer
- Solid Tumor Cancer